These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38002292)

  • 1. Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors.
    Salmaso V; Persico M; Da Ros T; Spalluto G; Kachler S; Klotz KN; Moro S; Federico S
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
    Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
    J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.
    Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Monopoli A; Ongini E; Varani K; Borea PA
    J Med Chem; 2002 Jan; 45(1):115-26. PubMed ID: 11754583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
    Federico S; Margiotta E; Salmaso V; Pastorin G; Kachler S; Klotz KN; Moro S; Spalluto G
    Eur J Med Chem; 2018 Sep; 157():837-851. PubMed ID: 30144700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A
    Federico S; Persico M; Trevisan L; Biasinutto C; Bolcato G; Salmaso V; Da Ros T; Gianferrara T; Prencipe F; Kachler S; Klotz KN; Pacor S; Moro S; Spalluto G
    ChemMedChem; 2023 Nov; 18(21):e202300299. PubMed ID: 37675643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.
    Federico S; Redenti S; Sturlese M; Ciancetta A; Kachler S; Klotz KN; Cacciari B; Moro S; Spalluto G
    PLoS One; 2015; 10(12):e0143504. PubMed ID: 26625265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
    Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
    Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
    J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists.
    Redenti S; Ciancetta A; Pastorin G; Cacciari B; Moro S; Spalluto G; Federico S
    Curr Top Med Chem; 2016; 16(28):3224-3257. PubMed ID: 27150365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
    J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
    Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S
    Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity.
    Varano F; Catarzi D; Falsini M; Dal Ben D; Buccioni M; Marucci G; Volpini R; Colotta V
    Bioorg Med Chem Lett; 2019 Feb; 29(4):563-569. PubMed ID: 30638876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.
    Baraldi PG; Cacciari B; Moro S; Spalluto G; Pastorin G; Da Ros T; Klotz KN; Varani K; Gessi S; Borea PA
    J Med Chem; 2002 Feb; 45(4):770-80. PubMed ID: 11831890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists.
    Burbiel JC; Ghattas W; Küppers P; Köse M; Lacher S; Herzner AM; Kombu RS; Akkinepally RR; Hockemeyer J; Müller CE
    ChemMedChem; 2016 Oct; 11(20):2272-2286. PubMed ID: 27531666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
    Squarcialupi L; Falsini M; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Dal Ben D; Lambertucci C; Volpini R; Colotta V
    Bioorg Med Chem; 2016 Jun; 24(12):2794-808. PubMed ID: 27161878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship study.
    Federico S; Ciancetta A; Porta N; Redenti S; Pastorin G; Cacciari B; Klotz KN; Moro S; Spalluto G
    J Med Chem; 2014 Jul; 57(14):6210-25. PubMed ID: 24972108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
    Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
    J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
    Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
    J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.